Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | KDM5A | P29375 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011373 | 0.87 | TGFBR1 (0.42) | MAPTTGFBR1KDM4ERECQLIRAK4 | |
| SCHEMBL2011183 | 0.81 | TGFBR1 (0.38) | MAPTTGFBR1KDM4EHTTRECQL | |
| SCHEMBL25335825 | 0.80 | TGFBR1 (0.37) | TGFBR1HTTLMNATP53SMN1; SMN2 | |
| SCHEMBL2008227 | 0.76 | TGFBR1 (0.40) | TGFBR1RECQLIRAK4 | |
| SCHEMBL16326405 | 0.76 | P2RY1 (0.46) | MAPTKDM4ELMNATP53GAA | |
| SCHEMBL2010390 | 0.74 | TGFBR1 (0.44) | TGFBR1LMNARECQLMAPK1ALDH1A1 | |
| SCHEMBL2013870 | 0.73 | TGFBR1 (0.43) | TGFBR1KDM5AKDM4CKDM5BIRAK4 | |
| SCHEMBL17949431 | 0.73 | SMN1; SMN2 (0.33) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6985382 | 0.71 | PDE4A (0.40) | KDM4ELMNAMAPK1ALDH1A1 | |
| SCHEMBL4315973 | 0.71 | TGFBR1 (0.45) | MAPTTGFBR1KDM4EHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938289-B2 | Therapeutic pyrazolyl thienopyridines | FBM THERAPEUTICS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9260450-B2 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2527345-B1 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS INC (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9090625-B2 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150175624-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140031385-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | Medicis Phamaceutical Corporation (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2074128-B1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | MEDICIS PHARMACEUTICAL CORP (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8455512-B2 | Therapeutic pyrazolyl thienopyridines | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110224251-A1 | Therapeutic Pyrazolyl Thienopyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| US-7964612-B2 | Therapeutic pyrazolyl thienopyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2074128-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | Pfizer Products Incorporated (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008047198-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031385-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | MAPT 3677/4885TGFBR1 1/4885KDM5A 1512/4885 |
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | MAPT 3677/4885TGFBR1 1/4885KDM5A 1512/4885 |
| US-20110224251-A1 | Therapeutic Pyrazolyl Thienopyridines | TGFBR1, SMAD3, TGFBR2 | MAPT 3677/4885TGFBR1 1/4885KDM5A 1512/4885 |
| US-20150175624-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | MAPT 3677/4885TGFBR1 1/4885KDM5A 1512/4885 |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | ACVR1, TGFBR1, ACVRL1 | MAPT 4596/4885TGFBR1 2/4885KDM5A 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.